Abbott's Coronary IVL IDE Study

Inclusion Criteria:

1. Subject must be at least 18 years of age.

2. Subject must sign and date a written informed consent form before any study-specifictests or procedures are performed.

3. Subject is able and willing to comply with all protocol requirements.

4. Subject has native coronary artery disease (including stable or unstable angina andsilent ischemia) suitable for PCI.

5. For subject with unstable ischemic heart disease, cardiac biomarker (troponin) mustbe less than or equal to the upper reference limit (URL) within 12 hours prior tothe procedure.

6. For subject with stable ischemic heart disease, blood for cardiac biomarkers may bedrawn prior to the procedure or at the time of the procedure from the side port ofthe sheath.

6a. If drawn prior to the procedure, cardiac biomarker (troponin) must be less than or equal to the URL within 12 hours prior to the index procedure.

6b. If drawn at the time of the procedure from the side port of the sheath prior to any intervention, cardiac biomarker results need to be analyzed and resulted prior to registering the subject into the study.

7. Left ventricular ejection fraction (LVEF) ≥ 25% within 6 months (note: in the caseof multiple assessments of LVEF, the measurement closest to enrollment will be usedfor these criteria; may be assessed at time of index procedure).

8. Lesions in non-target vessels requiring PCI may be treated either: a. >30 days priorto the study procedure if the procedure was unsuccessful or complicated; or b. >24hours prior to the study procedure if the procedure was successful anduncomplicated; or c. >30 days after the study procedure (in 1 or 2 non-targetvessels).

Anatomic Inclusion Criteria

Anatomic inclusion criteria are applied at the time of cardiac catheterization for PCI by the investigator and are visually assessed by angiography. The anatomic inclusion criteria include the following:

1. The target lesion must be a single de novo coronary lesion that has not beenpreviously treated with ANY interventional procedure.

2. Single de novo target lesion stenosis of protected left main coronary artery (LMCA),or left anterior descending artery (LAD), right coronary artery (RCA), leftcircumflex artery (LCX), or ramus intermedius (RI), or of their branches with: a.Stenosis of ≥70% and <100% or b. Stenosis ≥50% and <70% with evidence of ischemiavia positive stress test, or fractional flow reserve (FFR) value ≤0.80, or RFR/iFR <0.89 (or any other non-hyperemic pressure index), or IVUS or OCT minimum lumen area ≤4.0 mm^2

3. The target vessel reference diameter must be ≥2.5 mm and ≤4.0 mm.

4. The lesion length must not exceed 36 mm. 4a) Tandem lesions are allowed andconsidered one lesion if they are <5 mm apart and as long as the total lesion lengthdoes not exceed 36 mm.

5. The target vessel must have TIMI grade 3 flow at baseline; may be assessed afterpre-dilatation.

6. Evidence of calcification at the lesion site by, a. Angiography, with fluoroscopicradiopacities noted as severe (radiopacities noted without cardiac motion beforecontrast injection compromising both sides of the arterial lumen) OR b. IVUS or OCT,with presence of ≥270 degrees of calcium on at least 1 cross section.

7. Ability to pass a 0.014" guide wire across the lesion.

Exclusion Criteria:

1. Subject has other anatomic or comorbid conditions, or other medical, social, orpsychological conditions that, in the investigator's opinion, could limit thesubject's ability to participate in the clinical investigation or to comply withfollow-up requirements of the clinical investigation results.

2. Subject is a member of a vulnerable population including individuals with mentaldisability, persons in nursing homes, children, impoverished persons, persons inemergency situations, homeless persons, nomads, refugees, and those incapable ofgiving informed consent.

3. Subject is participating in another research study involving an investigationalagent (pharmaceutical, biologic, or medical device) that has not reached the Primaryendpoint. For the purposes of this criterion, "participation" is defined as beingregistered in another trial.

4. Pregnant or nursing subjects and those who plan pregnancy during the clinicalinvestigation follow-up period. For subjects with childbearing potential, a urine orblood pregnancy test is required within 7 days prior to index procedure to verifythat subject is not pregnant. Note: Investigators should instruct female patients ofchildbearing potential to use safe contraception for 12 months after the procedure (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants,transdermal patches, hormonal vaginal devices, injections with prolonged release).It is acceptable to include subjects having a sterilized regular partner.

5. Subject unable to tolerate dual antiplatelet therapy (i.e., aspirin, and eitherclopidogrel, prasugrel, or ticagrelor) for at least 6 months.

6. Subject has an allergy to imaging contrast media which cannot be adequatelypre-medicated.

7. Subject experienced an acute MI (either ST-segment elevation myocardial infarction,STEMI or non-ST-segment elevation myocardial infarction, NSTEMI) within 30 daysprior to index procedure, defined as a clinical syndrome consistent with an acutecoronary syndrome with troponin or CK- MB greater than 1 times the locallaboratory's ULN.

8. Subject has New York Heart Association (NYHA) class III or IV heart failure.

9. Subject has renal failure with serum creatinine >2.5 mg/dL, or chronic dialysis.

10. Subject has a history of a stroke or transient ischemic attack (TIA) within 6months, or any prior intracranial hemorrhage or permanent neurologic deficit.

11. Subject has an active peptic ulcer or upper gastrointestinal bleeding within 6months.

12. Subject has an untreated pre-procedural hemoglobin <10 g/dL or intention to refuseblood transfusions if one should become necessary.

13. Subject has a coagulopathy, including but not limited to platelet count <100,000 orInternational Normalized ratio (INR) >1.7 (INR is only required in subjects who havetaken warfarin within 2 weeks of enrollment).

14. Subject has a hypercoagulable disorder such as polycythemia vera, platelet count >750,000 or other disorders.

15. Subject has uncontrolled diabetes defined as a HbA1c ≥10%.

16. Subject has an active systemic infection on the day of the index procedure witheither fever, leukocytosis or requiring intravenous antibiotics.

17. Subject in cardiogenic shock or with clinical evidence of left-sided heart failure (S3 gallop, pulmonary rales, oliguria, or hypoxemia).

18. Subject has uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg).

19. Subject with a life expectancy of less than 1 year.

20. Subject has had non-coronary interventional (e.g., TAVR, MitraClip, or PFOocclusion, etc.) or surgical structural heart procedures within 30 days prior to theindex procedure.

21. Subject has planned non-coronary interventional (e.g., TAVR, MitraClip, or PFOocclusion, etc.) or surgical structural heart procedures within 30 days after theindex procedure.

22. Subject refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery.

23. Subject has a previous stent in the target vessel implanted within the last year.

24. Planned use of atherectomy, scoring or cutting balloon, ultra-high pressurenon-compliant balloon, excimer laser coronary atherectomy (ELCA), drug-coatedballoon (DCB) or any investigational device other than the current study device

Anatomic Exclusion Criteria

Anatomic exclusion criteria are applied at the time of cardiac catheterization for PCI by the investigator and are visually assessed by angiography. The anatomic exclusion criteria include the following:

1. Unprotected LMCA diameter stenosis >30%.

2. Target lesion has a myocardial bridge.

3. Target vessel is excessively tortuous, defined as the presence of 2 or more bends >90 degrees or 3 or more bends >75 degrees.

4. Definite or possible thrombus in the target vessel.

5. Evidence of aneurysm in target vessel within 10 mm of the target lesion.

6. Target lesion in ostial location (LAD, RCA, LCX, or RI, within 5 mm of ostium) or anunprotected LMCA lesion.

7. Target lesion is a bifurcation with ostial diameter stenosis ≥30%.

8. Second lesion with >50% stenosis in the same target vessel as the target lesion,including its side branches that are ≥2.0 mm in diameter.

9. Target lesion is located in a native vessel that can only be reached by goingthrough an existing coronary artery bypass graft.

10. Any previous stent within 10 mm of the target lesion.

11. Imaging evidence of a dissection (NHLBI dissection grades D-F) in the target vesselafter guide wire passage and/or prior to start of IVL treatment